Body mass index–based predictions and personalized clinical strategies for colorectal cancer in the context of PPPM
Open Access
- 2 December 2022
- journal article
- review article
- Published by Springer Nature in EPMA Journal
- Vol. 13 (4) , 615-632
Abstract
Currently colorectal cancer (CRC) is the third most prevalent cancer worldwide. Body mass index (BMI) is frequently used in CRC screening and risk assessment to quantitatively evaluate weight. However, the impact of BMI on clinical strategies for CRC has received little attention. Within the framework of the predictive, preventive, and personalized medicine (3PM/PPPM), we hypothesized that BMI stratification would affect the primary, secondary, and tertiary care options for CRC and we conducted a critical evidence-based review. BMI dynamically influences CRC outcomes, which helps avoiding adverse treatment effects. The outcome of surgical and radiation treatment is adversely affected by overweight (BMI ≥ 30) or underweight (BMI < 20). A number of interventions, such as enhanced recovery after surgery and robotic surgery, can be applied to CRC at all levels of BMI. BMI-controlling modalities such as exercise, diet control, nutritional therapy, and medications may be potentially beneficial for patients with CRC. Patients with overweight are advised to lose weight through diet, medication, and physical activity while patients suffering of underweight require more focus on nutrition. BMI assists patients with CRC in better managing their weight, which decreases the incidence of adverse prognostic events during treatment. BMI is accessible, noninvasive, and highly predictive of clinical outcomes in CRC. The cost–benefit of the PPPM paradigm in developing countries can be advanced, and the clinical benefit for patients can be improved with the promotion of BMI-based clinical strategy models for CRC.Keywords
Funding Information
- National Natural Science Foundation of China (82174501, 81973955, 82004474)
This publication has 160 references indexed in Scilit:
- Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapyMedical Oncology, 2013
- Short‐ and long‐term impact of body mass index on laparoscopic rectal cancer surgeryColorectal Disease, 2013
- Individualized nutrition intervention is of major benefit to colorectal cancer patients: long-term follow-up of a randomized controlled trial of nutritional therapyThe American Journal of Clinical Nutrition, 2012
- Previous transanal full‐thickness excision increases the morbidity of radical resection for rectal cancerColorectal Disease, 2012
- Outcome of laparoscopic colorectal surgery in obese and nonobese patients: a meta-analysisSurgical Endoscopy, 2011
- Cancer diagnostics and treatment: are we ready to implement PPPM?EPMA Journal, 2010
- Impact of Body Mass Index and Weight Change After Treatment on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From Cancer and Leukemia Group B 89803Journal of Clinical Oncology, 2008
- Influence of obesity on the risk of developing colon cancerGut, 2005
- The impact of obesity on the short-term andlong-term outcomes after percutaneous coronary intervention: the obesity paradox?JACC, 2002
- Leptin is a growth factor for human colon cancer cellsGastroenterology, 2001